Niagen Bioscience Execs to Debate Aging Science at Canaccord Well Summit
Event summary
- Niagen Bioscience CEO Rob Fried and CFO Ozan Pamir to speak at Canaccord Genuity’s Well Summit (Sept. 28-30, 2026)
- Fried scheduled for 'Aging on Trial' panel on Sept. 29, 11:15 AM ET
- Company highlights NAD+ science focus and Tru Niagen’s #1 U.S. market position
- Niagen Plus pharmaceutical-grade IV/injectable products available by prescription
- NAD Pharmaceuticals subsidiary developing NB4168 for aging and rare diseases
The big picture
Niagen Bioscience’s participation in Canaccord’s Well Summit underscores the growing institutional interest in healthy aging science. The company’s focus on NAD+ boosters positions it in the emerging intersection of consumer wellness and pharmaceutical development. With Tru Niagen maintaining U.S. market leadership and its subsidiary exploring therapeutic applications, Niagen Bioscience appears to be executing a dual-track strategy of direct-to-consumer sales and potential medical applications.
What we're watching
- Market Positioning
- How Niagen Bioscience will leverage its NAD+ authority to differentiate in the crowded healthy aging sector
- Regulatory Pathways
- The pace at which NAD Pharmaceuticals advances NB4168 through clinical development
- Commercial Strategy
- Whether the prescription-only Niagen Plus products can expand beyond current clinic distribution